EGFR and neoplasm: Non-invasive molecular imaging agents, such as anti-EGFR monoclonal antibodies conjugated MR constrast, Tc-99m 8B6 Nanobody, F-18 Affibody protein, C-11 erlotinib, Lu-177 nimotuzumab, and C-11 4-N-(3-bromoanilino)-6, 7-dimethoxyquinazoline, have been developed for evaluating EGFR status of tumor [6–10].